| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A cure for HIV: how would we know?
|
Zerbato, Jennifer M
|
|
|
7 |
5 |
p. e304-e306
|
artikel
|
| 2 |
A story of bad blood, corruption, and politics
|
Burki, Talha
|
|
|
7 |
5 |
p. e321
|
artikel
|
| 3 |
COVID-19 in patients with HIV: clinical case series
|
Blanco, Jose L
|
|
|
7 |
5 |
p. e314-e316
|
artikel
|
| 4 |
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial
|
Kintu, Kenneth
|
|
|
7 |
5 |
p. e332-e339
|
artikel
|
| 5 |
Enrolling pregnant women with HIV into clinical trials
|
Orkin, Chloe
|
|
|
7 |
5 |
p. e302-e303
|
artikel
|
| 6 |
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report
|
Gupta, Ravindra Kumar
|
|
|
7 |
5 |
p. e340-e347
|
artikel
|
| 7 |
Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations
|
Vannakit, Ravipa
|
|
|
7 |
5 |
p. e366-e372
|
artikel
|
| 8 |
HIV-related stigma among health-care workers in the MENA region
|
Ballouz, Tala
|
|
|
7 |
5 |
p. e311-e313
|
artikel
|
| 9 |
How universal does universal test and treat have to be?
|
Baggaley, Rebecca F
|
|
|
7 |
5 |
p. e306-e308
|
artikel
|
| 10 |
Is increasing pretreatment HIV drug resistance a real menace or minor detail?
|
Inzaule, Seth C
|
|
|
7 |
5 |
p. e316-e317
|
artikel
|
| 11 |
Is increasing pretreatment HIV drug resistance a real menace or minor detail? – Authors' reply
|
Chung, Michael H
|
|
|
7 |
5 |
p. e317-e318
|
artikel
|
| 12 |
Maintaining HIV care during the COVID-19 pandemic
|
Jiang, Hongbo
|
|
|
7 |
5 |
p. e308-e309
|
artikel
|
| 13 |
Opportunities and limits for dolutegravir in late pregnancy
|
Kufa, Tendesayi
|
|
|
7 |
5 |
p. e303-e304
|
artikel
|
| 14 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
|
João, Esaú C
|
|
|
7 |
5 |
p. e322-e331
|
artikel
|
| 15 |
The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study
|
Akullian, Adam
|
|
|
7 |
5 |
p. e348-e358
|
artikel
|
| 16 |
The HIV-1 antibody response: a footprint of the viral reservoir in children vertically infected with HIV
|
Palma, Paolo
|
|
|
7 |
5 |
p. e359-e365
|
artikel
|
| 17 |
Three lessons for the COVID-19 response from pandemic HIV
|
Hargreaves, James
|
|
|
7 |
5 |
p. e309-e311
|
artikel
|
| 18 |
Tuberculosis and HIV responses threatened by COVID-19
|
Adepoju, Paul
|
|
|
7 |
5 |
p. e319-e320
|
artikel
|
| 19 |
When pandemics collide
|
The Lancet HIV,
|
|
|
7 |
5 |
p. e301
|
artikel
|
Tijdschrift beschrijving